NASDAQ:OVAS - OvaScience Stock Price, Price Target & More

$0.8701 0.00 (0.00 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$0.8701
Today's Range$0.8531 - $0.8999
52-Week Range$0.71 - $1.96
Volume86,585 shs
Average Volume860,513 shs
Market Capitalization$31.01 million
P/E Ratio-0.66
Dividend YieldN/A
Beta3.2

About OvaScience (NASDAQ:OVAS)

OvaScience logoOvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company's portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient's own ovarian tissue. The Company's AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient's own EggPC cells are added to the patient's mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman's ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman's own EggPC cells without the need for hormone hyperstimulation.

Receive OVAS News and Ratings via Email

Sign-up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OVAS
CUSIPN/A
Phone617-500-2802

Debt

Debt-to-Equity RatioN/A
Current Ratio8.82%
Quick Ratio8.82%

Price-To-Earnings

Trailing P/E Ratio-0.66
Forward P/E Ratio-0.72
P/E GrowthN/A

Sales & Book Value

Annual Sales$290,000.00
Price / Sales107.17
Cash FlowN/A
Price / CashN/A
Book Value$1.80 per share
Price / Book0.48

Profitability

EPS (Most Recent Fiscal Year)($1.32)
Net Income$-50,970,000.00
Net Margins-17,338.78%
Return on Equity-60.06%
Return on Assets-52.85%

Miscellaneous

Employees36
Outstanding Shares35,720,000

How to Become a New Pot Stock Millionaire

OvaScience (NASDAQ:OVAS) Frequently Asked Questions

What is OvaScience's stock symbol?

OvaScience trades on the NASDAQ under the ticker symbol "OVAS."

How were OvaScience's earnings last quarter?

OvaScience (NASDAQ:OVAS) released its earnings results on Thursday, March, 15th. The biotechnology company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.07. The biotechnology company earned $0.09 million during the quarter, compared to analyst estimates of $0.10 million. OvaScience had a negative net margin of 17,338.78% and a negative return on equity of 60.06%. View OvaScience's Earnings History.

When is OvaScience's next earnings date?

OvaScience is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for OvaScience.

What price target have analysts set for OVAS?

2 equities research analysts have issued 1 year target prices for OvaScience's shares. Their forecasts range from $15.00 to $15.00. On average, they expect OvaScience's stock price to reach $15.00 in the next year. View Analyst Ratings for OvaScience.

What are Wall Street analysts saying about OvaScience stock?

Here are some recent quotes from research analysts about OvaScience stock:
  • 1. HC Wainwright analysts commented, "Refocus on Science Should Aid in the Long Term; Reit Buy Incremental progress as the company seeks to capitalize upon its internal expertise in cell biology. On yesterday’s 4Q17 call, the company provided an update on the OvaPrime and OvaTure programs as management pivoted to a R&D-focused strategy. We think the key takeaways are two-fold: (1) the interim data from the first 20 patients in the Phase 1 trial of OvaPrime appear to deliver bittersweet news. The safety data look clean, but no strong signals were observed on the secondary endpoints that could suggest efficacy. As a result, this trial has terminated patient enrollment, and per management, the company will advance OvaPrime directly to a Phase 1b/2a study in 2H18 with an improved cell processing technique to hopefully improve efficacy." (3/16/2018)
  • 2. According to Zacks Investment Research, "OvaScience, Inc. is a life science company focused on the discovery, development and commercialization of new treatments for infertility. Its product includes Augment for the treatment of infertility and Ova Ture used in the creation of mature fertilizable eggs. Ova Science, Inc. is headquartered in Cambridge, Massachusetts. " (1/11/2018)

Who are some of OvaScience's key competitors?

Who are OvaScience's key executives?

OvaScience's management team includes the folowing people:
  • Christopher A. Kroeger M.D., Chief Executive Officer
  • Jonathan Gillis, principal Financial Officer, principal Accounting Officer, Vice President
  • Karen Long, Executive Vice President - Clinical and Regulatory Affairs and Quality Assurance
  • James Luterman Ph.D., Executive Vice President - Research and Development
  • Theresa McNeely, Executive Vice President, Chief Communications Officer (Age 51)
  • James Lillie, Chief Scientific Officer
  • Ravi Mehrotra Ph.D., Chief Corporate Development Officer
  • Richard H. Aldrich, Lead Independent Director (Age 62)
  • John P. Howe III M.D., Director (Age 67)
  • John E. Sexton Ph.D., Director

Has OvaScience been receiving favorable news coverage?

News headlines about OVAS stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. OvaScience earned a coverage optimism score of 0.18 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.79 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of OvaScience?

Shares of OVAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OvaScience's stock price today?

One share of OVAS stock can currently be purchased for approximately $0.8701.

How big of a company is OvaScience?

OvaScience has a market capitalization of $31.01 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-50,970,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. OvaScience employs 36 workers across the globe.

How can I contact OvaScience?

OvaScience's mailing address is 9 FOURTH AVENUE, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 617-500-2802 or via email at [email protected]


MarketBeat Community Rating for OvaScience (OVAS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  400
MarketBeat's community ratings are surveys of what our community members think about OvaScience and other stocks. Vote "Outperform" if you believe OVAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVAS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

OvaScience (NASDAQ:OVAS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for OvaScience in the last 12 months. Their average twelve-month price target is $15.00, suggesting that the stock has a possible upside of 1,623.94%. The high price target for OVAS is $15.00 and the low price target for OVAS is $15.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyHoldHoldHold
Consensus Rating Score: 2.502.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.00$8.00$8.00$8.00
Price Target Upside: 1,623.94% upside716.33% upside429.80% upside379.04% upside

OvaScience (NASDAQ:OVAS) Consensus Price Target History

Price Target History for OvaScience (NASDAQ:OVAS)

OvaScience (NASDAQ:OVAS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/16/2018HC WainwrightReiterated RatingBuy$15.00HighView Rating Details
8/3/2017OppenheimerReiterated RatingHoldLowView Rating Details
4/18/2017Credit Suisse GroupReiterated RatingUnderperform -> Underperform$1.00LowView Rating Details
8/10/2016JMP SecuritiesReiterated RatingNeutralN/AView Rating Details
8/5/2016JPMorgan ChaseLower Price TargetNeutral$9.00 -> $8.00N/AView Rating Details
5/8/2016Leerink SwannReiterated RatingHold$6.00 -> $7.00N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

OvaScience (NASDAQ:OVAS) Earnings History and Estimates Chart

Earnings by Quarter for OvaScience (NASDAQ:OVAS)

OvaScience (NASDAQ:OVAS) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.21 EPS
Next Year EPS Consensus Estimate: $-1.04 EPS

OvaScience (NASDAQ OVAS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018N/AView Earnings Details
3/15/2018Q4 2017($0.30)($0.23)$0.10 million$0.09 millionViewN/AView Earnings Details
11/2/2017Q3 2017($0.40)($0.25)$0.09 million$0.06 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.47)($0.45)$0.09 million$0.08 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.46)($0.38)$0.12 million$0.06 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.58)($0.64)$0.11 million$0.12 millionViewListenView Earnings Details
11/3/2016Q316($0.62)($0.54)$0.25 million$0.02 millionViewListenView Earnings Details
8/4/2016Q216($0.78)($0.62)$0.21 million$0.19 millionViewListenView Earnings Details
5/5/2016Q116($0.72)($0.80)$0.14 million$0.15 millionViewListenView Earnings Details
2/25/2016Q315($0.71)($0.76)$0.20 million$0.16 millionViewListenView Earnings Details
11/5/2015Q3($0.68)($0.66)$0.17 million$0.08 millionViewN/AView Earnings Details
8/10/2015Q215($0.64)($0.64)$0.57 million$0.03 millionViewN/AView Earnings Details
5/11/2015($0.65)($0.65)$0.40 million$0.02 millionViewN/AView Earnings Details
3/16/2015Q414($0.59)($0.79)ViewN/AView Earnings Details
11/10/2014Q314($0.44)($0.54)ViewN/AView Earnings Details
8/7/2014Q214($0.45)($0.42)ViewN/AView Earnings Details
5/8/2014($0.46)($0.41)ViewN/AView Earnings Details
2/27/2014Q413($0.39)($0.64)ViewN/AView Earnings Details
11/13/2013Q313($0.35)($0.40)ViewN/AView Earnings Details
8/13/2013Q213($0.28)($0.36)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.28)($0.39)ViewN/AView Earnings Details
2/25/2013Q4 2012($0.29)($0.33)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

OvaScience (NASDAQ:OVAS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

OvaScience (NASDAQ OVAS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.50%
Institutional Ownership Percentage: 43.88%
Insider Trading History for OvaScience (NASDAQ:OVAS)
Institutional Ownership by Quarter for OvaScience (NASDAQ:OVAS)

OvaScience (NASDAQ OVAS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/1/2016Michelle DippCEOBuy425,000$7.00$2,975,000.00971,921View SEC Filing  
5/18/2016Michelle DippCEOBuy20,000$7.86$157,200.00971,921View SEC Filing  
5/17/2016Michelle DippCEOBuy40,000$7.63$305,200.00971,921View SEC Filing  
5/13/2016Richard AldrichDirectorBuy36,095$6.94$250,499.30604,185View SEC Filing  
5/11/2016Richard AldrichDirectorBuy20,000$7.64$152,800.00604,185View SEC Filing  
5/10/2016Michelle DippCEOBuy19,900$7.72$153,628.00971,921View SEC Filing  
5/10/2016Paul W.D. ChapmanCOOBuy3,100$7.37$22,847.003,100View SEC Filing  
3/24/2016Michelle DippCEOBuy59,800$9.49$567,502.00971,921View SEC Filing  
3/22/2016Michelle DippCEOBuy59,800$10.44$624,312.00971,921View SEC Filing  
3/18/2016Michelle DippCEOBuy59,700$8.26$493,122.00971,921View SEC Filing  
3/16/2016Michelle DippCEOBuy59,029$7.90$466,329.10971,921View SEC Filing  
3/14/2016Michelle DippCEOBuy162,732$7.60$1,236,763.20971,921View SEC Filing  
10/5/2015Jeffrey E YoungCFOBuy3,450$10.70$36,915.003,750View SEC Filing  
10/5/2015Marc D KozinDirectorBuy4,800$10.79$51,792.0020,553View SEC Filing  
9/9/2015Mary FisherDirectorBuy6,100$16.49$100,589.006,415View SEC Filing  
9/8/2015Marc D KozinDirectorBuy3,000$17.60$52,800.0014,612View SEC Filing  
4/8/2015Marc D KozinDirectorBuy3,000$28.45$85,350.00View SEC Filing  
4/2/2015Michelle DippCEOBuy1,000$32.49$32,490.00View SEC Filing  
1/13/2015Thomas MalleyDirectorBuy35,000$50.00$1,750,000.00View SEC Filing  
7/7/2014Richard AldrichDirectorBuy2,000$9.49$18,980.00View SEC Filing  
6/30/2014Richard AldrichDirectorBuy2,000$9.16$18,320.00View SEC Filing  
6/23/2014Richard AldrichDirectorBuy2,000$8.81$17,620.00View SEC Filing  
6/16/2014Richard AldrichDirectorBuy2,000$8.52$17,040.00View SEC Filing  
6/9/2014Richard AldrichDirectorBuy2,000$7.59$15,180.00View SEC Filing  
6/3/2014Harald F StockDirectorBuy1,063$7.01$7,451.63View SEC Filing  
6/2/2014Richard AldrichDirectorBuy2,000$7.29$14,580.00View SEC Filing  
5/27/2014Richard AldrichDirectorBuy2,000$7.50$15,000.00View SEC Filing  
5/20/2014Harald F StockDirectorBuy1,050$7.13$7,486.50View SEC Filing  
5/19/2014Richard AldrichDirectorBuy2,000$7.33$14,660.00View SEC Filing  
3/7/2014Fund L.P. LongwoodMajor ShareholderBuy100,000$10.00$1,000,000.00View SEC Filing  
9/12/2013Arthur TzianabosInsiderBuy1,000$10.32$10,320.00View SEC Filing  
9/12/2013Harald F StockDirectorBuy4,500$10.64$47,880.00View SEC Filing  
9/11/2013Christopher A BleckInsiderBuy2,000$11.15$22,300.00View SEC Filing  
9/11/2013Richard AldrichDirectorBuy4,850$10.54$51,119.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

OvaScience (NASDAQ OVAS) News Headlines

Source:
DateHeadline
OvaScience (OVAS) Stock Rating Lowered by Zacks Investment ResearchOvaScience (OVAS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 18 at 5:18 PM
OvaScience (OVAS) Given "Hold" Rating at OppenheimerOvaScience (OVAS) Given "Hold" Rating at Oppenheimer
www.americanbankingnews.com - April 13 at 10:53 AM
OvaScience (OVAS) Upgraded by Zacks Investment Research to "Hold"OvaScience (OVAS) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 12 at 1:45 PM
OvaScience (OVAS) Receives Buy Rating from HC WainwrightOvaScience (OVAS) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - April 1 at 7:35 PM
OvaScience (OVAS) Downgraded by Zacks Investment ResearchOvaScience (OVAS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:00 AM
Whats Happening with These Biotech Stocks? -- OncoSec Medical, OvaScience, Pacific Biosciences of California, and Pieris PharmaWhat's Happening with These Biotech Stocks? -- OncoSec Medical, OvaScience, Pacific Biosciences of California, and Pieris Pharma
www.bizjournals.com - March 22 at 8:34 AM
OvaSciences (OVAS) CEO Christopher Kroeger on Q4 2017 Results - Earnings Call TranscriptOvaScience's (OVAS) CEO Christopher Kroeger on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 16 at 6:23 PM
Edited Transcript of OVAS earnings conference call or presentation 15-Mar-18 8:30pm GMTEdited Transcript of OVAS earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 6:23 PM
HC Wainwright Reaffirms Buy Rating for OvaScience (OVAS)HC Wainwright Reaffirms Buy Rating for OvaScience (OVAS)
www.americanbankingnews.com - March 16 at 3:00 PM
OvaScience Reports Fourth Quarter and Year-End 2017 Financial ... - Business Wire (press release)OvaScience Reports Fourth Quarter and Year-End 2017 Financial ... - Business Wire (press release)
www.businesswire.com - March 16 at 8:27 AM
OvaScience (OVAS) Posts  Earnings Results, Beats Expectations By $0.04 EPSOvaScience (OVAS) Posts Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - March 15 at 7:06 PM
Does OvaScience Inc’s (NASDAQ:OVAS) Past Performance Indicate A Stronger Future?Does OvaScience Inc’s (NASDAQ:OVAS) Past Performance Indicate A Stronger Future?
finance.yahoo.com - March 15 at 8:24 AM
OvaScience Reports Inducement Grant Under Nasdaq Listing Rule ... - Business Wire (press release)OvaScience Reports Inducement Grant Under Nasdaq Listing Rule ... - Business Wire (press release)
www.businesswire.com - March 13 at 8:33 AM
OvaScience Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)OvaScience Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - March 12 at 6:31 PM
OvaScience (OVAS) Set to Announce Quarterly Earnings on ThursdayOvaScience (OVAS) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 9 at 11:49 PM
OvaScience to Host Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call - Business Wire (press release)OvaScience to Host Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call - Business Wire (press release)
www.businesswire.com - March 8 at 6:30 PM
OvaScience to Host Fourth Quarter and Fiscal Year 2017 Financial Results Conference CallOvaScience to Host Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call
finance.yahoo.com - March 8 at 6:30 PM
Form 4 OvaScience, Inc. For: Mar 06 Filed by: Lillie James Woodruff - StreetInsider.comForm 4 OvaScience, Inc. For: Mar 06 Filed by: Lillie James Woodruff - StreetInsider.com
www.streetinsider.com - March 8 at 8:31 AM
Zacks: Analysts Anticipate OvaScience Inc (OVAS) Will Post Quarterly Sales of $100,000.00Zacks: Analysts Anticipate OvaScience Inc (OVAS) Will Post Quarterly Sales of $100,000.00
www.americanbankingnews.com - February 28 at 4:48 AM
 Brokerages Anticipate OvaScience Inc (OVAS) Will Post Earnings of -$0.30 Per Share Brokerages Anticipate OvaScience Inc (OVAS) Will Post Earnings of -$0.30 Per Share
www.americanbankingnews.com - February 26 at 1:18 PM
OvaScience (OVAS) Set to Announce Earnings on WednesdayOvaScience (OVAS) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 21 at 2:40 AM
Zacks: Brokerages Expect OvaScience Inc (OVAS) Will Post Quarterly Sales of $80,000.00Zacks: Brokerages Expect OvaScience Inc (OVAS) Will Post Quarterly Sales of $80,000.00
www.americanbankingnews.com - February 11 at 1:48 AM
 Analysts Anticipate OvaScience Inc (OVAS) Will Announce Earnings of -$0.29 Per Share Analysts Anticipate OvaScience Inc (OVAS) Will Announce Earnings of -$0.29 Per Share
www.americanbankingnews.com - February 9 at 9:08 PM
Why OvaScience Inc (NASDAQ:OVAS) Is A Financially Healthy CompanyWhy OvaScience Inc (NASDAQ:OVAS) Is A Financially Healthy Company
finance.yahoo.com - February 1 at 9:57 AM
Form 3 OvaScience, Inc. For: Jan 16 Filed by: Lillie James Woodruff - StreetInsider.comForm 3 OvaScience, Inc. For: Jan 16 Filed by: Lillie James Woodruff - StreetInsider.com
www.streetinsider.com - January 24 at 8:12 AM
 Brokerages Expect OvaScience Inc (OVAS) to Post -$0.29 Earnings Per Share Brokerages Expect OvaScience Inc (OVAS) to Post -$0.29 Earnings Per Share
www.americanbankingnews.com - January 23 at 11:06 PM
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline - January 22, 2018FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline - January 22, 2018
finance.yahoo.com - January 22 at 3:59 PM
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline - January 22, 2018DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline - January 22, 2018
finance.yahoo.com - January 18 at 11:30 AM
OVAS INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of OvaScience, Inc. Investors and Encourages Investors to ...OVAS INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of OvaScience, Inc. Investors and Encourages Investors to ...
www.businesswire.com - January 17 at 4:35 PM
OVAS INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of OvaScience, Inc. Investors and Encourages Investors to Contact the FirmOVAS INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of OvaScience, Inc. Investors and Encourages Investors to Contact the Firm
finance.yahoo.com - January 17 at 4:35 PM
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against OvaScience, Inc. (OVAS) and Encourages Investors to Contact the Firm Before January 22, 2018Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against OvaScience, Inc. (OVAS) and Encourages Investors to Contact the Firm Before January 22, 2018
finance.yahoo.com - January 17 at 10:18 AM
Financial Survey: OvaScience (OVAS) vs. Chromadex (CDXC)Financial Survey: OvaScience (OVAS) vs. Chromadex (CDXC)
www.americanbankingnews.com - January 15 at 3:32 AM
OvaScience (OVAS) and The Competition Financial ComparisonOvaScience (OVAS) and The Competition Financial Comparison
www.americanbankingnews.com - January 14 at 5:28 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline - January 22, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline - January 22, 2018
finance.yahoo.com - January 12 at 4:25 PM
OvaScience (OVAS) Upgraded to "Buy" by Zacks Investment ResearchOvaScience (OVAS) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - January 10 at 6:00 AM
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against OvaScience, Inc. (OVAS) and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against OvaScience, Inc. (OVAS) and Encourages Investors to Contact the Firm
finance.yahoo.com - January 9 at 10:17 AM
OvaScience Inc (OVAS) Expected to Post Quarterly Sales of $80,000.00OvaScience Inc (OVAS) Expected to Post Quarterly Sales of $80,000.00
www.americanbankingnews.com - January 8 at 7:02 AM
 Brokerages Expect OvaScience Inc (OVAS) Will Announce Earnings of -$0.29 Per Share Brokerages Expect OvaScience Inc (OVAS) Will Announce Earnings of -$0.29 Per Share
www.americanbankingnews.com - January 6 at 7:14 PM
Pomerantz LLP: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OvaScience, Inc. - OVASPomerantz LLP: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OvaScience, Inc. - OVAS
www.finanznachrichten.de - January 5 at 4:15 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline – January 22, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline – January 22, 2018
finance.yahoo.com - January 5 at 10:34 AM
OvaScience (OVAS) versus Its Peers Critical SurveyOvaScience (OVAS) versus Its Peers Critical Survey
www.americanbankingnews.com - January 4 at 11:06 PM
Recros Medica Closes $9M Financing, Strengthens BoardRecros Medica Closes $9M Financing, Strengthens Board
finance.yahoo.com - January 4 at 10:20 AM
Announces Corporate Update - Business Wire (press release)Announces Corporate Update - Business Wire (press release)
www.businesswire.com - January 3 at 4:34 PM
OvaScienceSM Announces Corporate UpdateOvaScienceSM Announces Corporate Update
finance.yahoo.com - January 3 at 4:34 PM
Head to Head Review: OvaScience (OVAS) & The CompetitionHead to Head Review: OvaScience (OVAS) & The Competition
www.americanbankingnews.com - January 2 at 9:14 PM
Critical Comparison: OvaScience (OVAS) and Its RivalsCritical Comparison: OvaScience (OVAS) and Its Rivals
www.americanbankingnews.com - January 1 at 3:28 AM
OvaScience (OVAS) vs. The Competition Financial SurveyOvaScience (OVAS) vs. The Competition Financial Survey
www.americanbankingnews.com - December 31 at 10:06 PM
Head to Head Contrast: OvaScience (OVAS) versus Its RivalsHead to Head Contrast: OvaScience (OVAS) versus Its Rivals
www.americanbankingnews.com - December 26 at 9:24 AM
Oncobiologics (ONS) & OvaScience (OVAS) Critical SurveyOncobiologics (ONS) & OvaScience (OVAS) Critical Survey
www.americanbankingnews.com - December 24 at 3:54 AM
OvaScience Inc. (OVAS) Expected to Post Quarterly Sales of $80,000.00OvaScience Inc. (OVAS) Expected to Post Quarterly Sales of $80,000.00
www.americanbankingnews.com - December 23 at 8:30 AM

SEC Filings

OvaScience (NASDAQ:OVAS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

OvaScience (NASDAQ:OVAS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

OvaScience (NASDAQ OVAS) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.